Press Releases.

Initiated Third and Final Cohort of the Multiple Ascending Dose Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

FDA Removal of Partial Clinical Hold for Phase I Multiple Ascending Dose Study of RGLS4326

Regulus Plans to Re-Initiate Clinical Studies in Q1 2020

Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326

Closing of First Tranche of $41.8 Million Private Placement of Equity

Data Requirements Defined To Reinitiate Multiple Ascending Dose And Chronic Dose Studies With RGLS4326

Closing of First Tranche of $41.8 Million Private Placement of Equity

Term Loan Amended to Provide Up to Two Years of Interest Only Payments and Extension of Maturity Date to May 2022

Up to $41.8 Million in Gross Proceeds to be Funded in Two Tranches

Favorable Pharmacological Properties Exhibited in Preclinical Models of NASH

No Adverse or Other Significant Findings to Date Across All Dose Groups Tested

Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival

$47 Million Restructured Sanofi Collaboration Executed

Sanofi Will Assume Development of RG-012 for Alport syndrome

Hepatitis B virus Lead Compound Demonstrates Compelling Data in Preclinical Studies

Corporate Restructuring and Pipeline Focus Expected to Extend Cash Runway

Efforts Aimed at Extending Cash Runway to mid-2019

Two pre-clinical programs advance towards clinical candidates

Conference Call and Webcast to Follow

Initial safety and pharmacokinetic results from single ascending dose study support advancement

Full enrollment of RG-012 studies anticipated in 2H 2018

Conference Call and Webcast to Follow

Conference Call Today at 5:00 p.m. ET

Conference Call and Webcast to Follow

Completed Public Offering Raising $46 Million in Gross Proceeds

Conference Call and Webcast to Follow

Phase II RG-012 HERA and Renal Biopsy studies for Alport syndrome move forward

Company to Restructure Operations Accompanied by a Workforce Reduction

Conference Call and Webcast to Follow

RG-012 development program to include a separate biopsy study, which may provide earlier POC

Conference Call and Webcast to Follow

Published results from preclinical studies show inhibition of miR-17 increased survival and reduced disease burden in mice

FDA requests longer-term follow-up data from ongoing studies

Conference Call Today at 5:00 p.m. ET

Conference Call and Webcast to Follow

Conference Call Today at 5:00 p.m. ET

On Track to Deliver Follow-up Results from On-going RG-101 Studies

Conference Call and Webcast to Follow

Timelines of On-going Studies are not Expected to be Impacted

- Results Demonstrate First Successful Shortened 4-week Treatment Regimen to Date -

- Phase II Study Evaluating the Combination of RG-101 and GSK's Long-Acting Parenteral (LAP) Formulation of GSK2878175 as a potential single-visit cure to begin Q4 2016

- Continued High Virologic Response Rates across All Treatment Arms Out through 24 weeks of Follow Up -

-Oral presentation during general session on interim RG-101 Phase II results & three posters to be presented-

- RG-101 Containing Regimen Has Potential to Reduce Harvoni®, Olysio®, or Daklinza™ Rx to 4 Week Duration -

- Additional studies on track for enrollment in H12016 with multiple data read-outs expected throughout 2016 -

-Regulus Earns $10.0 Million Milestone Payment from AstraZeneca and Achieves Key Goal for 2015-